Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$481.00M$481.00M+47.7% vs Q2 2025 Net Income$229.91M$229.91M+39.2% vs Q2 2025 EPS Diluted$1.90$1.90+42.9% vs Q2 2025 Operating Income$287,654,000+42.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$236,718,000+141.2% Margins · derivedOperating margin59.8%−2.3 pt vs Q2 2025
Net margin47.8%−2.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end